

24 July 2014

By E-Lodgement

National Stock Exchange of Australia
Level 34,
50 Bridge Street
Sydney NSW 2000

Market Announcement – Change of Company Secretary

In accordance with rule 6.17 (4) of Section IIA of the NSX Listing and Business Rules, IQNovate Limited (NSX:IQN) advises that Mr Spiro Sakiris has resigned as Company Secretary of IQNovate Limited in order to concentrate on his dual role as Chief Financial Officer and Chief Operating Officer.

Mr Kelvin Boateng, LLB, BEc, GradDip(Leg), who holds the position of Head, Legal and Commercial Affairs with IQNovate Limited, has been appointed Company Secretary effective 22 July 2014. Mr Boateng will be the nominated person for all communication with the NSX regarding listing rules matters and other disclosure issues.



Kevin Boateng

Company Secretary

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQNovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE IQNovate Limited

IQNovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, IQNovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.

IQNovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.